U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H11NO.C4H6O4
Molecular Weight 255.2671
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMOXYPINE SUCCINATE

SMILES

OC(=O)CCC(O)=O.CCC1=C(O)C=CC(C)=N1

InChI

InChIKey=IKMNOGHPKNFPTK-UHFFFAOYSA-N
InChI=1S/C8H11NO.C4H6O4/c1-3-7-8(10)5-4-6(2)9-7;5-3(6)1-2-4(7)8/h4-5,10H,3H2,1-2H3;1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI

Molecular Formula C8H11NO
Molecular Weight 137.179
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Emoxypine (ethylmethylhydroxypyridine) succinate (MEXIDOL®) is a 3-hydroxypyridine derivative which is quite similar in structure to Vitamin B6 (pyridoxine). The most important components of the mechanism of action of Mexidol® are its antioxidant and membranotropic effects, the ability to modulate functioning of receptors and membrane-bound enzymes, restore a neurotransmitter balance. Due to its mechanism of action Mexidol® has a wide range of pharmacological effects, realized on at least two levels – neuronal and vascular. It has antihypoxic, anti-ischemic, neuroprotective, nootropic, vegetotrophic, anti-stress, anxiolytic, anticonvulsant, anti-alcohol, cardioprotective, anti-atherogenic, geroprotective and other actions. Under the action of Mexidol®, it is observed an improvement in cerebral circulation and microcirculation. Emoxypine is distributed in Russia but it is widely unknown in other regions.

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
[Efficacy of emoxypine in combined therapy for elderly patients with postinfarct cardiosclerosis and heart failure].
2004
[Correction by 2-ethyl-6-methyl-3-hydroxypyridine succinate of the hepatotoxyc, caused at rats introduction tuberculostatics].
2004
[Use of mexidol in stomatology: results and perspectives].
2004
[Xerostomia. Diagnosis and treatment].
2004
[Clinical and biochemical manifestations of chronic pyelonephritis and their correction in population of the northen areas of the Tyumen Territory].
2004
[Effect of typical and atypical anxiolytics on the behavior and electrophysiological parameters of rats with model cerebrovascular pathology].
2004 Nov-Dec
[Investigation of the effects of mexidol in escapable and inescapable emotional stress in inbred BALB/C and C57BL/6 mice].
2004 Nov-Dec
[Pharmacological correction of memory impairment caused by a complex extremal action in mice with bilateral ligation of common carotid arteries].
2004 Sep-Oct
[Protective effect of activators of biological oxidation in nitrite intoxication in rats].
2005
[The treatment of patients with toxic encephalopathy caused by using surrogate psychoactive manganese-containing compounds].
2005
[Effects of mexidol on the antioxidative status of patients suffering from coronary heart disease with dislipidemia].
2005
[Effects of emoxipine, reamberine and mexidol on neuropathic symptoms and a systolic function of the left ventricular myocardium in patients with diabetes mellitus and diabetic foot syndrome].
2005
[Methodological bases of early psychosocial rehabilitation of poststroke patients in neurological hospital].
2005
[Effect of mexicor on oxidative stress in acute myocardial infarction].
2005
[Results of application of synthetic antioxidants in treatment of patients with destructive pancreatitis].
2005
Antihypoxic and antinecrotic effect of mexidol in skin ischemia.
2005 Feb
[Biotransformation of mexidol in inbred BALB/C and C57BL/6 mice].
2005 Mar-Apr
[Antinecrotic and antiischemic effect of mexidol and trental in ischemia of the skin graft].
2005 May
[Mexidol in treatment of children with generalized epilepsy and febrile seizures].
2005 May
The effects of Mexidol on the acquisition of food-related conditioned reflexes and synaptic ultrastructure in field CA1 of the rat hippocampus after single acoustic stimuli with ultrasonic components.
2005 May
[Study of antiradical activity of new compounds by chemiluminescence].
2005 May-Jun
[Metabolic effects of mexidole during cardiosurgical operations using extracorporeal circulation].
2005 May-Jun
[Mexidol corrects model post-reanimation changes in cerebral lipid metabolism].
2005 May-Jun
Lymphotropic effect of mexidol in reactive fever.
2005 Oct
Activity of nitric oxide synthase and concentration of nitric oxide end metabolites in the gingiva under experimental pathological conditions.
2005 Oct
[Antihypoxant activity and mechanisms of action of some natural and synthetic compounds].
2005 Sep-Oct
[Estimating the potential of antioxidant therapy for patients with Parkinson's disease diagnosis].
2005 Sep-Oct
[A comparative study of the development of drug differentiation between mexidol and phenazepam].
2005 Sep-Oct
[The experimental study of peculiarities and mechanism of neuroprotective action of mexidol in hemorrhagic stroke].
2006
[The use of mexidol in urgent treatment of drug addiction].
2006
[Mexidol in combined treatment of acute pancreatitis].
2006
[Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy].
2006
[Lipid reducing and antioxidant action of mexicor in patients with diabetes mellitus type 2].
2006
[Antioxidants in complex treatment of Parkinson's disease].
2006
[Neurometabolic therapy of diabetic neuropathy].
2006
[Complex therapy of acute and exacerbated chronic nonspecific parotitis including mexidol and non-coherent infrared therapy].
2006
[The use of mexidol in psychiatric practice].
2006
[Neureprotective drugs efficiency in patients with chronic tension headaches].
2006
[Antistressor and analgesic effects of mexidol, diazepam, paracetamol, and their combinations].
2006 Jul-Aug
[The effectiveness of ascorbic acid and emoxipin in treatment of infiltrative pulmonary tuberculosis].
2007
[The efficacy of complex therapy of ventricular arrhythmias with emoxipin and preductal in combination with antiarrhythmic agents].
2007
[Influence of gel Metrogil Denta and curative toothpaste Mexidol Dent activ on indices of parodontal status and lipid peroxidation in patients with chronic generalized catarrhal gingivitis].
2007
Lymphotropic effect of dimephosphon, mexidol, and ketorolac is realized via activation of the lymphangion and stimulation of lymph formation.
2007 Apr
[The effect of rubomycin, mexidol and emoxypine on some metabolic indexes and the proccess of spontaneous metastasis under conditions of experimental neoplasia].
2007 Jan-Feb
[Acute radiation sickness in experiment. Efficacy of mexidol].
2007 Jul-Sep
[Effect of mexidol on hemopoietic system in conditions of an emotional stress after exposure to ionizing radiation].
2007 Mar-Apr
[Combined action of mexidol and non-narcotic analgesics on pain thresholds and emotional stress behavior in animals].
2007 Mar-Apr
[Pharmacological correction of neuronal damage in sensomotor zone of frontal cortex under conditions of experimental cerebral blood flow pathology].
2007 Nov-Dec
[The regulatory effect of mexidol on the hemoglobin level under acute stress conditions].
2007 Sep-Oct
[Experience with complex treatment for childhood amblyopia].
2008 Jan-Feb
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.
Route of Administration: intravenous, intramuscular, oral
Substance Class Chemical
Created
by admin
on Mon Oct 21 23:30:43 UTC 2019
Edited
by admin
on Mon Oct 21 23:30:43 UTC 2019
Record UNII
2R985002CT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EMOXYPINE SUCCINATE
Common Name English
3-PYRIDINOL, 2-ETHYL-6-METHYL-, BUTANEDIOATE (1:1) (SALT)
Common Name English
MEXIPRIM
Common Name English
MEXIDOL
Common Name English
METHYLETHYLPIRIDINOL SUCCINATE [WHO-DD]
Common Name English
METHYLETHYLPIRIDINOL SUCCINATE
WHO-DD  
Common Name English
MEXICOR
Common Name English
BUTANEDIOIC ACID, COMPD. WITH 2-ETHYL-6-METHYL-3-PYRIDINOL (1:1)
Common Name English
EMICIDINE
Common Name English
EMICIDIN
Common Name English
Code System Code Type Description
CAS
127464-43-1
Created by admin on Mon Oct 21 23:30:43 UTC 2019 , Edited by admin on Mon Oct 21 23:30:43 UTC 2019
PRIMARY
EPA CompTox
127464-43-1
Created by admin on Mon Oct 21 23:30:43 UTC 2019 , Edited by admin on Mon Oct 21 23:30:43 UTC 2019
PRIMARY
PUBCHEM
122298
Created by admin on Mon Oct 21 23:30:43 UTC 2019 , Edited by admin on Mon Oct 21 23:30:43 UTC 2019
PRIMARY
MESH
C070020
Created by admin on Mon Oct 21 23:30:43 UTC 2019 , Edited by admin on Mon Oct 21 23:30:43 UTC 2019
PRIMARY
EVMPD
SUB35088
Created by admin on Mon Oct 21 23:30:43 UTC 2019 , Edited by admin on Mon Oct 21 23:30:43 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY